Pulmatrix (NASDAQ:PULM) Announces Earnings Results

Pulmatrix (NASDAQ:PULM) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, FiscalAI reports.

Pulmatrix Stock Up 2.7%

PULM traded up $0.08 during trading on Friday, reaching $2.99. The company had a trading volume of 12,356 shares, compared to its average volume of 14,066. The business has a 50 day simple moving average of $2.53 and a 200-day simple moving average of $3.94. Pulmatrix has a 52 week low of $2.15 and a 52 week high of $9.37.

Hedge Funds Weigh In On Pulmatrix

A number of large investors have recently made changes to their positions in PULM. Dimensional Fund Advisors LP bought a new position in Pulmatrix during the 3rd quarter valued at about $52,000. DRW Securities LLC purchased a new position in shares of Pulmatrix during the fourth quarter valued at approximately $46,000. Finally, SBI Securities Co. Ltd. boosted its position in shares of Pulmatrix by 15.7% during the second quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 8,208 shares during the period. 11.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).